Missed their end point in the Phase IIB study, but still think there is value here. Selling off today as a result, but company looking at numbers, more to come I believe with a couple other drugs still in the pipeline. Institutional ownership is high on this one also, over 80 %. Big boys don't look to lose their $. Could be oversold, may be a buying opportunity here at today's prices./ok2